Back to Search
Start Over
The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.
- Source :
- Blood; November 2009, Vol. 114 Issue: 22 p1124-1124, 1p
- Publication Year :
- 2009
-
Abstract
- Abstract 1124
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 114
- Issue :
- 22
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs56791689
- Full Text :
- https://doi.org/10.1182/blood.V114.22.1124.1124